Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix 4th quarter 2025 earni ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix fourth quarter 2025 ea ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker4Standing by. Welcome to the Biodesix 4th quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 agai ...

Core Insights - Biodesix, Inc. is set to present preliminary data from the CLARIFY study at the 2025 CHEST Annual Meeting, focusing on lung nodule management and the performance of Nodify tests [1][2]. Group 1: CLARIFY Study Overview - The CLARIFY study aims to validate the performance of Nodify CDT and Nodify XL2 tests through a retrospective chart review of up to 4,000 patients, with a focus on diverse patient subgroups [2]. - The study began patient enrollment shortly after the 2024 CHEST Annual Meeting and has already enrolled 1,000 patients for interim analysis [2]. Group 2: Presentations at CHEST Annual Meeting - A national analysis on lung nodule management will be presented, emphasizing the need for structured approaches to optimize healthcare resource utilization and improve patient outcomes [3]. - Multiple independent presentations will highlight the clinical value of Nodify Lung tests in various real-world patient populations [3]. Group 3: Additional Presentations - Specific presentations include comparisons of the Nodify XL2 test with PET/CT for evaluating malignancy in pulmonary nodules and the impact of Nodify Lung Test strategy in risk stratification [4]. - Other topics include the association of lung cancer screening with proteomic testing in minority communities and retrospective analyses of Biodesix biomarkers [4]. Group 4: Company Vision and Market Context - Biodesix emphasizes the transformative potential of biomarkers in lung diagnostics, coinciding with Lung Cancer Awareness Month starting November 1 [5]. - The company is dedicated to improving clinical care and outcomes for patients with lung disease through its diagnostic tests and development services [5].